Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilvelestat sodium for mild to moderate pulmonary ARDS (prospective multicenter randomized double-blind placebo-controlled Phase 4 study)
ChiCTR2300068314Phase 4Recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing Test group (cilvelestat sodium) with Control group (placebo) (2 arms). Primary endpoint: Oxygenation index (PaO2/FiO2). Started Feb 2023; status: recruiting.
02
Drugs
sivelestat
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on ChiCTR2300068314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068314.